001     255487
005     20240112171752.0
024 7 _ |a pmc:PMC10192042
|2 pmc
024 7 _ |a 10.1002/ana.26608
|2 doi
024 7 _ |a pmid:36695634
|2 pmid
024 7 _ |a 0364-5134
|2 ISSN
024 7 _ |a 1531-8249
|2 ISSN
024 7 _ |a altmetric:141778768
|2 altmetric
037 _ _ |a DZNE-2023-00288
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Billingsley, Kimberley J
|0 0000-0002-8003-4029
|b 0
245 _ _ |a Genome-Wide Analysis of Structural Variants in Parkinson Disease.
260 _ _ |a Hoboken, NJ
|c 2023
|b Wiley-Blackwell
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1683031619_12620
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a CC BY-NC
520 _ _ |a Identification of genetic risk factors for Parkinson disease (PD) has to date been primarily limited to the study of single nucleotide variants, which only represent a small fraction of the genetic variation in the human genome. Consequently, causal variants for most PD risk are not known. Here we focused on structural variants (SVs), which represent a major source of genetic variation in the human genome. We aimed to discover SVs associated with PD risk by performing the first large-scale characterization of SVs in PD.We leveraged a recently developed computational pipeline to detect and genotype SVs from 7,772 Illumina short-read whole genome sequencing samples. Using this set of SV variants, we performed a genome-wide association study using 2,585 cases and 2,779 controls and identified SVs associated with PD risk. Furthermore, to validate the presence of these variants, we generated a subset of matched whole-genome long-read sequencing data.We genotyped and tested 3,154 common SVs, representing over 412 million nucleotides of previously uncatalogued genetic variation. Using long-read sequencing data, we validated the presence of three novel deletion SVs that are associated with risk of PD from our initial association analysis, including a 2 kb intronic deletion within the gene LRRN4.We identified three SVs associated with genetic risk of PD. This study represents the most comprehensive assessment of the contribution of SVs to the genetic risk of PD to date. ANN NEUROL 2023;93:1012-1022.
536 _ _ |a 899 - ohne Topic (POF4-899)
|0 G:(DE-HGF)POF4-899
|c POF4-899
|f POF IV
|x 0
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 1
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Genome-Wide Association Study
|2 MeSH
650 _ 2 |a Parkinson Disease: genetics
|2 MeSH
650 _ 2 |a Genome, Human
|2 MeSH
650 _ 2 |a Whole Genome Sequencing
|2 MeSH
650 _ 2 |a Genotype
|2 MeSH
700 1 _ |a Ding, Jinhui
|b 1
700 1 _ |a Jerez, Pilar Alvarez
|b 2
700 1 _ |a Illarionova, Anastasia
|0 P:(DE-2719)2812762
|b 3
|u dzne
700 1 _ |a Levine, Kristin
|b 4
700 1 _ |a Grenn, Francis P
|b 5
700 1 _ |a Makarious, Mary B
|b 6
700 1 _ |a Moore, Anni
|b 7
700 1 _ |a Vitale, Daniel
|b 8
700 1 _ |a Reed, Xylena
|b 9
700 1 _ |a Hernandez, Dena
|0 P:(DE-HGF)0
|b 10
700 1 _ |a Torkamani, Ali
|b 11
700 1 _ |a Ryten, Mina
|b 12
700 1 _ |a Hardy, John
|b 13
700 1 _ |a Consortium, UK Brain Expression
|b 14
|e Collaboration Author
700 1 _ |a Chia, Ruth
|b 15
700 1 _ |a Scholz, Sonja W
|0 0000-0002-6623-0429
|b 16
700 1 _ |a Traynor, Bryan J
|b 17
700 1 _ |a Dalgard, Clifton L
|b 18
700 1 _ |a Ehrlich, Debra J
|b 19
700 1 _ |a Tanaka, Toshiko
|b 20
700 1 _ |a Ferrucci, Luigi
|b 21
700 1 _ |a Beach, Thomas G
|b 22
700 1 _ |a Serrano, Geidy E
|b 23
700 1 _ |a Quinn, John P
|b 24
700 1 _ |a Bubb, Vivien J
|b 25
700 1 _ |a Collins, Ryan L
|b 26
700 1 _ |a Zhao, Xuefang
|b 27
700 1 _ |a Walker, Mark
|b 28
700 1 _ |a Pierce-Hoffman, Emma
|b 29
700 1 _ |a Brand, Harrison
|b 30
700 1 _ |a Talkowski, Michael E
|b 31
700 1 _ |a Casey, Bradford
|0 0000-0002-2623-5997
|b 32
700 1 _ |a Cookson, Mark R
|b 33
700 1 _ |a Markham, Androo
|b 34
700 1 _ |a Nalls, Mike A
|b 35
700 1 _ |a Mahmoud, Medhat
|b 36
700 1 _ |a Sedlazeck, Fritz J
|b 37
700 1 _ |a Blauwendraat, Cornelis
|0 P:(DE-2719)2810837
|b 38
|u dzne
700 1 _ |a Gibbs, J Raphael
|0 0000-0002-6985-0658
|b 39
700 1 _ |a Singleton, Andrew B
|b 40
773 _ _ |a 10.1002/ana.26608
|g p. ana.26608
|0 PERI:(DE-600)2037912-2
|n 5
|p 1012-1022
|t Annals of neurology
|v 93
|y 2023
|x 0364-5134
856 4 _ |u https://pub.dzne.de/record/255487/files/DZNE-2023-00288.pdf
|y OpenAccess
856 4 _ |u https://pub.dzne.de/record/255487/files/DZNE-2023-00288.pdf?subformat=pdfa
|x pdfa
|y OpenAccess
909 C O |o oai:pub.dzne.de:255487
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)2812762
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 38
|6 P:(DE-2719)2810837
913 1 _ |a DE-HGF
|b Programmungebundene Forschung
|l ohne Programm
|1 G:(DE-HGF)POF4-890
|0 G:(DE-HGF)POF4-899
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-800
|4 G:(DE-HGF)POF
|v ohne Topic
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 1
914 1 _ |y 2023
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2022-11-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2022-11-30
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2022-11-30
|w ger
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2022-11-30
915 _ _ |a Creative Commons Attribution-NonCommercial CC BY-NC 4.0
|0 LIC:(DE-HGF)CCBYNC4
|2 HGFVOC
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2023-10-24
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-10-24
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ANN NEUROL : 2022
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-10-24
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-10-24
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b ANN NEUROL : 2022
|d 2023-10-24
920 1 _ |0 I:(DE-2719)1240005
|k Core ICRU
|l Core ICRU
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1240005
980 _ _ |a UNRESTRICTED
980 1 _ |a FullTexts


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21